Details for New Drug Application (NDA): 021367

✉ Email this page to a colleague

NDA 021367 describes FEMRING, which is a drug marketed by Millicent Pr and is included in one NDA. It is available from one supplier. Additional details are available on the FEMRING profile page.

The generic ingredient in FEMRING is estradiol acetate. There are seventy-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the estradiol acetate profile page.

Summary for 021367

Tradename:	FEMRING
Applicant:	Millicent Pr
Ingredient:	estradiol acetate
Patents:	0

Pharmacology for NDA: 021367

Mechanism of Action	Estrogen Receptor Agonists

Suppliers and Packaging for NDA: 021367

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367	NDA	Millicent US, Inc.	72495-201	72495-201-05	1 POUCH in 1 CARTON (72495-201-05) / 90 d in 1 POUCH
FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367	NDA	Millicent US, Inc.	72495-202	72495-202-10	1 POUCH in 1 CARTON (72495-202-10) / 90 d in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INSERT, EXTENDED RELEASE;VAGINAL			Strength	EQ 0.05MG BASE/24HR
Approval Date:	Mar 20, 2003	TE:		RLD:	Yes

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INSERT, EXTENDED RELEASE;VAGINAL			Strength	EQ 0.1MG BASE/24HR
Approval Date:	Mar 20, 2003	TE:		RLD:	Yes

Expired US Patents for NDA 021367

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Millicent Pr	FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367-001	Mar 20, 2003	⤷ Get Started Free	⤷ Get Started Free
Millicent Pr	FEMRING	estradiol acetate	INSERT, EXTENDED RELEASE;VAGINAL	021367-002	Mar 20, 2003	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.